Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
Cancers
|
April 3, 2021
Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells
Thuy T Tran, Chetan K Rane, Christopher R Zito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2018
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
Harriet M Kluger, Veronica Chiang, Amit Mahajan, et al.
Cancer Immunology Research
|
July 21, 2023
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance
Irina Krykbaeva, Kate Bridges, William Damsky, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Nicholas D Klemen, Melinda Wang, Paul L Feingold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Sarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Sarah A Weiss, Mario Sznol, Montaser Shaheen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 18, 2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Sarah A Weiss, Dijana Djureinovic, Shlomit Jessel, et al.
Nature Immunology
|
July 27, 2021
Epigenetic scars of CD8<sup>+</sup> T cell exhaustion persist after cure of chronic infection in humans
Kathleen B Yates, Pierre Tonnerre, Genevieve E Martin, et al.
Molecular Cancer
|
November 15, 2023
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Dijana Djureinovic, Sarah A Weiss, Irina Krykbaeva, et al.
Nature
|
July 21, 2017
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T Manguso, Hans W Pope, Margaret D Zimmer, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
Cancers
|
April 3, 2021
Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells
Thuy T Tran, Chetan K Rane, Christopher R Zito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2018
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
Harriet M Kluger, Veronica Chiang, Amit Mahajan, et al.
Cancer Immunology Research
|
July 21, 2023
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance
Irina Krykbaeva, Kate Bridges, William Damsky, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Nicholas D Klemen, Melinda Wang, Paul L Feingold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Sarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Sarah A Weiss, Mario Sznol, Montaser Shaheen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 18, 2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Sarah A Weiss, Dijana Djureinovic, Shlomit Jessel, et al.
Nature Immunology
|
July 27, 2021
Epigenetic scars of CD8<sup>+</sup> T cell exhaustion persist after cure of chronic infection in humans
Kathleen B Yates, Pierre Tonnerre, Genevieve E Martin, et al.
Molecular Cancer
|
November 15, 2023
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Dijana Djureinovic, Sarah A Weiss, Irina Krykbaeva, et al.
Nature
|
July 21, 2017
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Robert T Manguso, Hans W Pope, Margaret D Zimmer, et al.
Page
of 5